Novo Nordisk Total Current Liabilities 2010-2024 | NVO

Novo Nordisk total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
  • Novo Nordisk total current liabilities for the quarter ending September 30, 2024 were $30.712B, a 21.91% increase year-over-year.
  • Novo Nordisk total current liabilities for 2023 were $24.634B, a 43.85% increase from 2022.
  • Novo Nordisk total current liabilities for 2022 were $17.125B, a 8.16% increase from 2021.
  • Novo Nordisk total current liabilities for 2021 were $15.833B, a 47.07% increase from 2020.
Novo Nordisk Annual Total Current Liabilities
(Millions of US $)
2023 $24,634
2022 $17,125
2021 $15,833
2020 $10,766
2019 $8,842
2018 $8,282
2017 $7,148
2016 $7,049
2015 $6,082
2014 $6,007
2013 $4,314
2012 $3,739
2011 $3,884
2010 $3,294
2009 $2,513
Novo Nordisk Quarterly Total Current Liabilities
(Millions of US $)
2024-09-30 $30,712
2024-06-30 $27,115
2024-03-31 $24,112
2023-12-31 $24,634
2023-09-30 $25,193
2023-06-30 $22,882
2023-03-31 $19,016
2022-12-31 $17,125
2022-09-30 $17,624
2022-06-30 $15,681
2022-03-31 $14,417
2021-12-31 $15,833
2021-09-30 $14,009
2021-06-30 $11,801
2021-03-31 $11,733
2020-12-31 $10,766
2020-09-30 $11,139
2020-06-30 $9,938
2020-03-31 $9,333
2019-12-31 $8,842
2019-09-30 $9,400
2019-06-30 $8,523
2019-03-31 $8,334
2018-12-31 $8,282
2018-09-30 $7,710
2018-06-30 $7,874
2018-03-31 $7,292
2017-12-31 $7,148
2017-09-30 $7,130
2017-06-30 $6,482
2017-03-31 $7,013
2016-12-31 $7,049
2016-09-30 $6,239
2016-06-30 $6,308
2016-03-31 $6,075
2015-12-31 $6,082
2015-09-30 $5,744
2015-06-30 $5,719
2015-03-31 $6,366
2014-12-31 $6,007
2014-09-30 $5,346
2014-06-30 $4,365
2014-03-31 $4,849
2013-12-31 $4,314
2013-09-30 $4,557
2013-06-30 $4,454
2013-03-31 $4,538
2012-12-31 $3,739
2012-09-30 $4,409
2012-06-30 $4,122
2012-03-31 $3,877
2011-12-31 $3,884
2011-09-30 $3,867
2011-06-30 $3,590
2011-03-31 $3,348
2010-12-31 $3,294
2010-09-30 $2,929
2010-06-30 $3,127
2010-03-31 $2,887
2009-12-31 $2,513
2009-09-30 $2,484
2009-06-30 $2,282
2009-03-31 $2,475
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $481.063B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51